Bridging the Gap in Customized Medicine: Navigating the Regulatory Landscapes of Compounding Pharmacies of India and the USA

Abstract

Compounding pharmacies in India compounding pharmacy and the US are a vital service to cater customised medicines made as per individual patient requirement. This paper hence intends to bridge a gap by exploring this function — such work has so far not been published on compounding pharmacies of India and their comparison with those in the USA. The pharmacies have a great significance and importance when the prescription or common medications are not available, do not work as per their effectiveness. The 2013 Drugs Quality and Security Act (DQSA) was developed in response to an outbreak of fungal meningitis related to the use of contaminated compounded medications and it regulates compounding pharmacies within the United States. The act divided compounding pharmacies into two types i.e., 503A and 503B facilities. There are pharmacies authorized to fill prescriptions which are 503A facilities, and those that create more compounded meds — meaning they mix or alter existing medicines in some way before handing them off for sale; these shops have FDA regulations up the wazoo. To ensure that the potency and quality is maintained, they also published the major recommendations which were established by The United States Pharmacopeia Convention (USP). In India, compounding pharmacies are under a variety of strict operating and licensing requirements. Although India's regulatory processes have well advanced, this paper examines how enforcing international standards could still provide additional safety and efficiency in the compounding of active pharmaceutical ingredients. The paper is concluding with saying that for compounded drugs both India and United States have developed regulatory frameworks. But there is requirement of cross-bordered cooperation and continued innovation so that the growing demand can be met for customized pharmaceuticals in the present global healthcare environment.